Difenoxin

Summary

Difenoxin (CHEMBL1201321) is an approved small-molecule antidiarrhoeal drug (ATC A07DA04).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A07DA04
• Chemistry: 424.5 Da · C28H28N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201321
Name	Difenoxin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	34328
ChEBI	CHEBI:4534
ATC	A07DA04
Molecular formula	C28H28N2O2
Molecular weight	424.5
InChIKey	UFIVBRCCIRTJTN-UHFFFAOYSA-N

SMILES: C1CN(CCC1(C2=CC=CC=C2)C(=O)O)CCC(C#N)(C3=CC=CC=C3)C4=CC=CC=C4

IUPAC name: 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid

ChEBI definition: A piperidinemonocarboxylic acid that is 4-phenylpiperidine-4-carboxylic acid in which the hydrogen attached to the nitrogen atom is substituted by a 3-cyano-3,3-diphenylpropyl group.

Pharmacological roles (ChEBI): antidiarrhoeal drug.

Also known as: Acscn-9168, Difenoxin, Difenoxina, Difenoxine, Diphenoxylate related compound a, Diphenoxylic acid, IDS-ND-007, Lyspafen, R 15,403 FREE BASE, R 15,403 [AS HYDROCHLORIDE], R-15403 FREE BASE, DIFENOXIN

Parent form; salt/anhydrous children: CHEMBL1200599

Patent coverage: 697 distinct patent families (2,393 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).